SSE

Banco Santander Chile Announces the Filing of Its Annual Report on Form 20-F With the United States Securities and Exchange Commission for Fiscal Year 2022

Retrieved on: 
Thursday, February 23, 2023
SSE, Banco Santander Chile, NYSE, Bank statement, Annual report, BSAC, Cryptocurrency

SANTIAGO, Chile, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Banco Santander Chile (“Santander Chile” or the “Company”) (NYSE: BSAC; SSE: Bsantander) announced today that its Annual Report on Form 20-F for the fiscal year ended December 31, 2022 (the “2022 Annual Report”) has been filed with the U.S. Securities and Exchange Commission (the “SEC”).

Key Points: 
  • SANTIAGO, Chile, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Banco Santander Chile (“Santander Chile” or the “Company”) (NYSE: BSAC; SSE: Bsantander) announced today that its Annual Report on Form 20-F for the fiscal year ended December 31, 2022 (the “2022 Annual Report”) has been filed with the U.S. Securities and Exchange Commission (the “SEC”).
  • The 2022 Annual Report can be accessed either by visiting the SEC's website at www.sec.gov or Santander Chile’s corporate website at www.santander.cl.
  • In addition, shareholders may receive a hard copy of the 2022 Annual Report, which includes the Company's complete audited financial statements, free of charge by requesting a copy from Santander Chile's Investor Relations Office at + 562 320 8284 or by email at: [email protected] .

Itaú Corpbanca Files Material Event Notice to Summoning to Annual General Shareholders’ Meeting

Retrieved on: 
Wednesday, February 22, 2023
SSE, NYSE, Financial market, Itaú Corpbanca, Rare-earth element, Grocery store

SANTIAGO, Chile, Feb. 22, 2023 (GLOBE NEWSWIRE) -- ITAÚ CORPBANCA (NYSE: ITCB; SSE: ITAUCORP) today announced that it filed a Material Event Notice with the Chilean Commission for the Financial Market reporting that Itaú Corpbanca scheduled the annual general shareholders’ meeting for April 20, 2023.

Key Points: 
  • SANTIAGO, Chile, Feb. 22, 2023 (GLOBE NEWSWIRE) -- ITAÚ CORPBANCA (NYSE: ITCB; SSE: ITAUCORP) today announced that it filed a Material Event Notice with the Chilean Commission for the Financial Market reporting that Itaú Corpbanca scheduled the annual general shareholders’ meeting for April 20, 2023.

SolarWinds to Host North American Transform Partner Summit, Emphasizing Company’s Growing Focus on Channel

Retrieved on: 
Wednesday, February 22, 2023
Networks, Internet, Data Management, Technology, Software, Cloud, Artificial Intelligence for IT Operations, Artificial intelligence, NYSE, Organization, SolarWinds, SWI, SCP, SSE, Automation, Growth, Accreditation, Machine learning, Observability, Video game

The event is part of a series of Partner Summits SolarWinds is hosting across Europe, Asia, and North America to provide information and support for the company’s channel partners.

Key Points: 
  • The event is part of a series of Partner Summits SolarWinds is hosting across Europe, Asia, and North America to provide information and support for the company’s channel partners.
  • At this year’s North American Partner Summit—which will be held live and in-person for the first time in two years—partners will be able to meet with SolarWinds executives, product experts, and other partners from North America.
  • “We launched the Transform Partner Program to continue our support of our partners' accelerating digital transformation efforts,” said Chad Reese, president of Americas sales and global channel at SolarWinds.
  • The SolarWinds North American Partner Summit will take place February 27 – March 3 in Austin, Texas.

Skyhigh Security Service Edge Completes IRAP Assessment to PROTECTED Level

Retrieved on: 
Wednesday, February 22, 2023
Public Policy, Government, Software, White House, Federal Government, Internet, Other Policy Issues, Data Management, Technology, Security, Cloud, CASB, Data loss prevention software, ACSC, Security Service, United States Department of Defense, Policy, ICT, Sky High, Computer security, Classification, Organization, ASD, Risk, ISM, SSE, DLP, SWG, FedRAMP, Australian Signals Directorate, Public sector, Federation, Impact, Medical device, IRAP

Skyhigh Security today announced its Skyhigh Security Service Edge (SSE) portfolio completed the Australian Information Security Registered Assessors Program (IRAP) assessment to the PROTECTED security classification level.

Key Points: 
  • Skyhigh Security today announced its Skyhigh Security Service Edge (SSE) portfolio completed the Australian Information Security Registered Assessors Program (IRAP) assessment to the PROTECTED security classification level.
  • The new assessment continues Skyhigh Security’s momentum in the federal government, following its previous completed assessment in 2020 where Skyhigh Cloud Access Security Broker (CASB) was assessed to the PROTECTED level.
  • Based on the completion of this Cloud Security Assessment, Skyhigh SSE has appropriate controls in place to meet the security objectives defined through the Australian Cybersecurity Centre’s (ACSC) Cloud Security Assessment and Authorisation Framework.
  • The Skyhigh SSE Portfolio includes Skyhigh SWG, Skyhigh CASB, Skyhigh Private Access and other products, integrated into a comprehensive cloud platform.

Bright Scholar Announces Appointment of Independent Director and Changes in Management

Retrieved on: 
Wednesday, February 22, 2023
SSE, Master of Business Administration, University, Global Association of Risk Professionals, Certified Financial Planner, Investment management, Government degree colleges in India, China Europe International Business School, Parkland, Bachelor of Commerce, NYSE, Economics, Commerce, Business administration, Oklahoma State University–Stillwater, Regulation, Regulation S-K, Research, University of International Relations, NN Group, SZSE, HKEX, Management, Limited

FOSHAN, China, Feb. 22, 2023 /PRNewswire/ -- Bright Scholar Education Holdings Limited ("Bright Scholar" or the "Company") (NYSE: BEDU), a global premier education service company, today announced appointment of an independent director to the board of directors of the Company (the "Board") and changes in its management.

Key Points: 
  • FOSHAN, China, Feb. 22, 2023 /PRNewswire/ -- Bright Scholar Education Holdings Limited ("Bright Scholar" or the "Company") (NYSE: BEDU), a global premier education service company, today announced appointment of an independent director to the board of directors of the Company (the "Board") and changes in its management.
  • The Company announced the appointment of Mr. Meng Rui as an independent director and the chairman of the audit committee of the Board.
  • Upon the effectiveness of Mr. Rui Meng's appointment, the Board consists of four directors, including two independent directors.
  • Bright Scholar thanks Ms. Wanmei Li for her efforts and contributions to the Company.

Junshi Biosciences Announces Toripalimab in Combination with Chemotherapy for Treatment of Advanced Triple-negative Breast Cancer Met Primary Endpoint in Phase 3 Clinical Study

Retrieved on: 
Tuesday, February 21, 2023
American Society of Clinical Oncology, SSE, IDMC, Immunotherapy, PD-1, III, Diagnosis, Breast cancer, Safety, Patient, Incidence, Recurrence, Research, Neoplasm, Risk, Triple-negative breast cancer, Survival, CSCO, Progression-free survival, Prognosis, Paclitaxel, COVID-19, Principal, PFS, HKEX, TNBC, Death, Anthracycline, Pharmaceutical industry, Chinese

According to GLOBOCAN 2020, breast cancer had the highest incidence rates worldwide, with 2.26 million new cases and 0.68 million deaths in 2020.

Key Points: 
  • According to GLOBOCAN 2020, breast cancer had the highest incidence rates worldwide, with 2.26 million new cases and 0.68 million deaths in 2020.
  • Amongst these breast cancer cases, triple-negative breast cancer (“TNBC”) accounted for approximately 15% to 20% of them.
  • However, to this day, no immunotherapy drugs have been approved for advanced TNBC in China, and chemotherapy remains the primary treatment option.
  • The TORCHLIGHT study is the first Phase III registration study in China to achieve a positive outcome in an advanced triple-negative breast cancer immunotherapy.

EIGHT COMPANIES JOIN CATALYST ACCELERATOR'S DEFENSIVE CYBER OPERATIONS FOR SPACE COHORT

Retrieved on: 
Friday, February 17, 2023
Software as a service, Organization, Rebel Space, SSE, Automation, CVE, Government, USSF, Internet of things, United States Department of Defense, Sherpa people, Orbit, VPN, Research, Defense, United States Space Force, Risk, Swap, THOR, Intelligence, Accelerator, DCO, Carrier syllabics, OT, Confidentiality, Catalysis, Communication, Environment, Private investigator, Arms industry, Cryptocurrency, Risk management, Smart Networks

Eight small businesses will come together from across the United States for the Catalyst Accelerator’s cohort focused on Defensive Cyber Operations for Space (DCO).

Key Points: 
  • Eight small businesses will come together from across the United States for the Catalyst Accelerator’s cohort focused on Defensive Cyber Operations for Space (DCO).
  • Therefore, the USSF, in conjunction with AFRL/RV, sought disruptive technologies and capabilities to aid in and further the mission of the warfighter for defensive cyber operations for space.
  • The Defensive Cyber Operations for Space cohort (#CADCO) will meet two weeks per month beginning March 7th and ending June 2nd.
  • Rebel Space Technologies (Long Beach, California) At Rebel Space, we advance the security of in-space communications and space systems for safer, more reliable commercial operations in low-earth orbit and beyond.

AXT, Inc. Announces Fourth Quarter and Fiscal Year 2022 Financial Results

Retrieved on: 
Thursday, February 16, 2023
Bank statement, SSE, Shanghai Stock Exchange, Shanghai Stock Exchange STAR Market, Beida Jade Bird Universal Sci-Tech, China Securities Regulatory Commission, GAAP, AXT, Star Market, IPO, Health, Tax, CSRC, Bank, Video game, Cryptocurrency

Revenue for the fourth quarter of 2022 was $26.8 million, compared with $35.2 million in the third quarter of 2022 and $37.7 million for the fourth quarter of 2021.

Key Points: 
  • Revenue for the fourth quarter of 2022 was $26.8 million, compared with $35.2 million in the third quarter of 2022 and $37.7 million for the fourth quarter of 2021.
  • GAAP gross margin was 32.1 percent of revenue for the fourth quarter of 2022, compared with 42.0 percent of revenue in the third quarter of 2022 and 32.2 percent for the fourth quarter of 2021.
  • This compares with $10.2 million in the third quarter of 2022 and $9.1 million for the fourth quarter of 2021.
  • Fiscal Year 2022 Results (January 1 to December 31, 2022)
    Revenue for fiscal year 2022 was $141.1 million, compared with $137.4 million in fiscal year 2021.

Junshi Biosciences and Coherus Announce Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Clinical Trial Evaluating Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma

Retrieved on: 
Wednesday, February 15, 2023
SSE, NPC, OS, Breakthrough therapy, Patient, Survival, Cisplatin, FDA, HKEX, ASCO, Pharmaceutical industry, Nature Medicine

SHANGHAI, China and REDWOOD CITY, Calif., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”) today announced positive results of a final analysis of overall survival (“OS”) from the pivotal study JUPITER-02 (NCT03581786), a randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating toripalimab in combination with gemcitabine and cisplatin as the first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma (“NPC”). This final analysis demonstrated a statistically significant and clinically meaningful improvement in OS in NPC patients treated with toripalimab plus chemotherapy compared to chemotherapy alone. These data are being submitted for presentation at an upcoming medical meeting.

Key Points: 
  • This final analysis demonstrated a statistically significant and clinically meaningful improvement in OS in NPC patients treated with toripalimab plus chemotherapy compared to chemotherapy alone.
  • These data are being submitted for presentation at an upcoming medical meeting.
  • “Compared to chemotherapy alone, a combination containing the immune checkpoint inhibitor, toripalimab, clearly has the potential to bring unprecedented changes to the extension of life in patients with NPC.
  • Recurrent or metastatic NPC is an aggressive head and neck tumor which has no FDA-approved treatment options.

Coherus and Junshi Biosciences Announce Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Clinical Trial Evaluating Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma

Retrieved on: 
Wednesday, February 15, 2023
SSE, NPC, OS, Breakthrough therapy, Patient, Survival, Cisplatin, FDA, CHRS, HKEX, ASCO, Pharmaceutical industry, Nature Medicine

This final analysis demonstrated a statistically significant and clinically meaningful improvement in OS in NPC patients treated with toripalimab plus chemotherapy compared to chemotherapy alone.

Key Points: 
  • This final analysis demonstrated a statistically significant and clinically meaningful improvement in OS in NPC patients treated with toripalimab plus chemotherapy compared to chemotherapy alone.
  • These data are being submitted for presentation at an upcoming medical meeting.
  • “Compared to chemotherapy alone, a combination containing the immune checkpoint inhibitor, toripalimab, clearly has the potential to bring unprecedented changes to the extension of life in patients with NPC.
  • Recurrent or metastatic NPC is an aggressive head and neck tumor which has no FDA-approved treatment options.